PODCAST: Energy Infrastructure under the Trump Administration — C&M's Trump: The First Year Series
Client Alert | 1 min read | 09.27.17
In the latest podcast for Crowell & Moring’s “Trump: The First Year” series, Richard Lehfeldt, partner in the firm’s Energy Group, and Diana Jeschke, counsel in the group, sit down to discuss energy infrastructure issues under the Trump Administration. Richard previously worked as counsel for the Energy and Power Subcommittee of the House Energy and Commerce Committee. Diana was an attorney advisor to administrative law judges Carmen Cintron and David Coffman at the Federal Energy Regulatory Commission.
Discussed in this 16-minute podcast:
- An overview of energy infrastructure.
- Who makes decisions about energy infrastructure, where does the funding originate, and what factors go into those decisions.
- An overview of distributed generation and microgrids.
- Case studies: NYU and Princeton University, and what lessons to take from them.
Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
